Facebook
Twitter
LinkedIn
ForwardNCCN 2018 Congress Series™: Acute Leukemia
During 2017 the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010. Progress in acute lymphoblastic leukemia (ALL) also leaped forward during 2017, with FDA approval of tisagenlecleucel, the first-ever chimeric antigen receptor (CAR) T cell therapy for patients with relapsed or refractory disease. While a cure for all acute leukemias remains elusive, great progress is being made. Clinicians need to be aware that recommendations for initiating, combining, and sequencing treatments are rapidly changing, along with guidelines for avoiding or managing adverse effects. All members of the oncology care team, and their patients, need a deeper understanding of the efficacy, safety, and side effect profiles of these novel agents.
NCCN's goal is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.
Hosted by The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Target Audience
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with acute leukemia.
Learning Objectives
Following this program, participants should be able to:
Impact of Changing Molecular Landscape on Leukemia Management
• Outline molecular markers used to guide clinical management of AML and ALL
• Identify emerging novel agents and targeted molecular markers in the management of relapsed or refractory AML
• Identify new provisional entities for AML and ALL based on the 2016 WHO classification update and emerging data
Advances in AML Management in Older Adults: Impact on Practice
• Describe the standard of care for older adults with AML
• Identify targetable molecular abnormalities in the management of AML
• Outline novel and emerging treatment options in the management of AML in older adults
Refractory ALL Management: New Insights
• Review the clinical data and discuss recent options for relapsed or refractory ALL treatment
• Summarize major adverse events that result from immunotherapy use in the management of relapsed or refractory ALL
• Identify novel agents being investigated in relapsed or refractory ALL management
Monitoring Minimal Residual Disease in Leukemia and Impact on Treatment
• Summarize current methods used to monitor minimal residual disease in acute lymphoblastic leukemia and acute myeloid leukemia
• Outline the clinical utility of MRD assessment in ALL clinical management
• Describe the clinical utility and caveats of the methods used to monitor minimal residual disease in AML
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Bhavana Bhatnagar, DO
Karyopharm Therapeutics: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria
Alice S. Mims, MD, MS
AbbVie, Inc.: Scientific Advisor
Agios, Inc.: Consulting Fees, Honoraria
Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Agios, Inc.: Consulting Fees, Honoraria
Argenx: Consulting Fees, Honoraria
Astellas Pharma US, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Consulting Fees, Honoraria
Celyad: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Consulting Fees, Honoraria
Pfizer Inc.: Consulting Fees, Honoraria; Grant/Research Support
Bijal Shah, MD
Amgen Inc.: Product/Speakers Bureau
Incyte Corporation: Grant/Research Support
Pharmacyclics: Consulting Fees, Honoraria
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson;
Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (Employed by NCCN until 8/10/18);
Joan S. McClure, MS (Employed by NCCN until 8/1/18); Lisa Perfidio, MS; Shannon Ryan;
Kathy Ann Smith, CMP, CHCP
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Ellen Erkess; Ndiya Ogba, PhD
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 medical knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Maintenance of Certification (MOC)
This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Maintenance of Certification program. Successful completion of this CME activity enables the participant to earn up to 4 Lifelong Learning (Part II) credits.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Medical Specialties (MOC)
Through the American Board of Specialties ("ABMS") MOC Initiative to create a wide array of Maintenance of Certification ("MOC") Activities through the ABMS MOC Directory, the NCCN 2018 Congress Series: Acute Leukemia has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Boards:
MOC Part II CME Activity
Radiology
Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board's general CME requirement (only). Please refer directly to your Member Board's MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 4 hours Category 1 credit for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 4 contact hours.
Pharmacists
| National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 4 contact hours (0.4 CEUs) of continuing education credit. UAN: 0836-0000-18-099-L01-P
Available Credit
- 4.00 ABIM MOC
- 4.00 AMA PRA Category 1 Credit™
- 4.00 ANCC contact hours
- 4.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for certificate viewing/printing